Guliz Ozgun
Clinical trials sponsored by Guliz Ozgun, explained in plain language.
-
Morning or afternoon? timing may boost kidney cancer treatment
Disease control Not yet recruitingThis study looks at whether getting standard immunotherapy drugs (nivolumab and ipilimumab) in the morning or afternoon makes them work better or cause fewer side effects in adults with advanced kidney cancer. About 142 participants will be randomly assigned to morning or afterno…
Phase: PHASE3 • Sponsor: Guliz Ozgun • Aim: Disease control
Last updated May 26, 2026 12:11 UTC
-
TIMING IS EVERYTHING: new study tests if morning or afternoon chemo beats bladder cancer better
Symptom relief Not yet recruitingThis study looks at whether giving standard advanced bladder cancer drugs (enfortumab vedotin and pembrolizumab) in the morning or afternoon changes how well they work or how bad the side effects are. About 224 adults with advanced bladder cancer will be randomly assigned to get …
Phase: PHASE3 • Sponsor: Guliz Ozgun • Aim: Symptom relief
Last updated May 22, 2026 14:01 UTC